Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16284
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Parakh, Sagun | - |
dc.contributor.author | Thursfield, Vicky | - |
dc.contributor.author | Cher, Lawrence M | - |
dc.contributor.author | Dally, Michael | - |
dc.contributor.author | Drummond, Katharine J | - |
dc.contributor.author | Murphy, Michael | - |
dc.contributor.author | Rosenthal, Mark A | - |
dc.contributor.author | Gan, Hui K | - |
dc.date | 2015-11-06 | - |
dc.date.accessioned | 2016-09-25T05:58:33Z | - |
dc.date.available | 2016-09-25T05:58:33Z | - |
dc.date.issued | 2016-02 | - |
dc.identifier.citation | Journal of Clinical Neuroscience 2016; 24: 78-82 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16284 | - |
dc.description.abstract | This retrospective population-based survey examined current patterns of care for patients with recurrent glioblastoma (rGBM) who had previously undergone surgery and post-operative therapy at original diagnosis. The patients were identified from the Victorian Cancer Registry (VCR) from 2006 to 2008. Patient demographics, tumour characteristics and oncological management were extracted using a standardised survey by the treating clinicians/VCR staff and results analysed by the VCR. Kaplan–Meier estimates of overall survival (OS) at diagnosis and progression were calculated. A total of 95 patients (48%) received treatment for first recurrence; craniotomy and post-operative treatment (38), craniotomy only (34) and non-surgical treatment (23). Patients receiving treatment at first progression had a higher median OS than those who did not (7 versus 3 months, p < 0.0001). All patients progressed after treatment for first progression with 43 patients (45%) receiving treatment at second progression. To our knowledge this is the first population-based pattern of care survey of treatment for rGBM in an era where post-operative “Stupp” chemo-radiation is standard. First and second line therapy for rGBM is common and associated with significant benefit. Treatment generally includes re-resection and/or systemic therapy. | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Recurrent glioblastoma | en_US |
dc.subject | Survival | en_US |
dc.title | Recurrent glioblastoma: current patterns of care in an Australian population | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Journal of Clinical Neuroscience | en_US |
dc.identifier.affiliation | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Alfred Health, Prahran, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Surgery, Melbourne University, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | St. Vincent’s Hospital, Fitzroy, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, Australia | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/26549675 | en_US |
dc.identifier.doi | 10.1016/j.jocn.2015.08.025 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Cher, Lawrence M | |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.